Adipotide
FTPP / Prohibitin-TP01
Adipotide (also known as FTPP or Prohibitin-TP01) is a chimeric peptide consisting of a prohibitin-targeting sequence fused to a pro-apoptotic peptide (D(KLAKLAK)2) that selectively destroys blood vessels supplying white adipose tissue, causing rapid and dramatic fat loss through vascular disruption. It was developed at the University of Texas MD Anderson Cancer Center and demonstrated remarkable fat reduction in obese rhesus monkeys, generating significant media attention. However, severe renal toxicity observed in primate studies has significantly tempered enthusiasm for its clinical development.
作用機序
Peptidomimetic that targets prohibitin on adipose vasculature. Binds to ANXA2 receptors on blood vessels supplying white adipose tissue, triggering targeted apoptosis of fat tissue endothelial cells. Causes selective fat tissue vascular disruption and subsequent fat cell death.
研究プロトコル
研究目的のみで使用。医療アドバイスではありません。
Research protocols in primates used 0.43mg/kg subcutaneously daily for 28 days. Resulted in 11% body weight loss. Human dosing not established. Very aggressive mechanism with significant renal toxicity risk.
研究ノート
Clinical Research Status
Adipotide demonstrated dramatic efficacy in a landmark 2012 primate study published in Science Translational Medicine, showing 11% body weight loss and 38% reduction in abdominal fat in obese rhesus monkeys over 28 days of treatment. Despite these impressive results, the severe kidney damage observed in treated animals has prevented progression to human clinical trials. No active clinical trial registrations for Adipotide in humans have been identified, and its development status remains uncertain with no recent publications from the original research group.
Key Published Findings
The targeting peptide CKGGRAKDC binds to prohibitin on the surface of blood vessels specifically in white adipose tissue, while the attached D(KLAKLAK)2 sequence disrupts mitochondrial membranes in endothelial cells, causing vascular collapse and subsequent adipocyte death. Treated monkeys showed dramatic reductions in body weight, BMI, abdominal circumference, and improvements in insulin resistance. Imaging studies confirmed selective destruction of adipose vasculature with corresponding fat tissue necrosis and reabsorption over the treatment period.
Safety Profile
The most significant safety concern is dose-dependent renal proximal tubule degeneration, likely due to prohibitin expression in kidney vasculature or renal filtration and accumulation of the peptide. Treated primates developed elevated BUN and creatinine levels, with histological evidence of tubular necrosis that was partially reversible upon treatment cessation. Additional concerns include the irreversible nature of vascular destruction in adipose tissue and the unknown long-term consequences of acute fat tissue necrosis on systemic inflammation and metabolic homeostasis.
Comparison to Related Compounds
Adipotide's mechanism is fundamentally different from all other fat loss compounds: rather than modulating metabolism, appetite, or lipolysis, it physically destroys the blood supply to fat tissue. GLP-1 agonists like semaglutide achieve comparable weight loss through appetite suppression without organ toxicity, making them far safer alternatives despite slower onset. The targeted vascular disruption approach was originally developed for cancer therapy (tumor angiogenesis inhibition) and represents a repurposing that may carry inherent toxicity risks in non-tumor tissue.
Community Observations
Despite significant interest generated by the primate study results, human self-experimentation with Adipotide is extremely rare due to legitimate fears of irreversible kidney damage. Online communities generally regard Adipotide as a cautionary example of dramatic efficacy coupled with unacceptable toxicity, often referenced in discussions about risk-reward calculations in experimental compound use. The compound is occasionally available from gray market peptide sources, but knowledgeable community members consistently advise against its use given the availability of safer alternatives for fat loss.
半減期
~30-60 minutes
再構成
Bacteriostatic water (BAC)
保存
乾燥粉末
Refrigerate 2-8C. Protect from light.
再溶解
Refrigerate 2-8C. Use within 7 days.
米国法的状況
また知られる名前
よくある質問
Adipotideとは何ですか?
Adipotide (also known as FTPP or Prohibitin-TP01) is a chimeric peptide consisting of a prohibitin-targeting sequence fused to a pro-apoptotic peptide (D(KLAKLAK)2) that selectively destroys blood vessels supplying white adipose tissue, causing rapid and dramatic fat loss through vascular disruption. It was developed at the University of Texas MD Anderson Cancer Center and demonstrated remarkable fat reduction in obese rhesus monkeys, generating significant media attention. However, severe renal toxicity observed in primate studies has significantly tempered enthusiasm for its clinical development.
Adipotideはどのように作用しますか?
Peptidomimetic that targets prohibitin on adipose vasculature. Binds to ANXA2 receptors on blood vessels supplying white adipose tissue, triggering targeted apoptosis of fat tissue endothelial cells. Causes selective fat tissue vascular disruption and subsequent fat cell death.
Adipotideの米国での規制状況は?
Research chemical (not FDA-approved)
Adipotideの半減期は?
~30-60 minutes
Adipotideの別名は?
FTPP, Prohibitin-TP01
ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。
完全な免責事項を読む